News

Zacks.com on MSN20h
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...
Market Inference7h
Supernus Pharmaceuticals Acquires Sage Therapeutics for $795 Million
The collaboration revenue from net sales of zurzuvae was $36.1 million for the full year 2024 and $13.8 million for the first ...
Tumblr’s content filtering systems have been falsely flagging posts as ‘mature,’ users blame AI
Tumblr users are complaining that content is being falsely labeled as mature, the latest tech company to grapple with ...
Post-Partum Depression Market Size Drug Pipeline Analysis, Treatment, Trends, And Rising Global Prevalence 2025-2035
Post-Partum Depression Market Size | Drug Pipeline Analysis, Treatment, Trends, and Rising Global Prevalence 2025-2035 The report provides a detailed analysis of the current post-partum depression ...